Efficacy of different regimens in nasal NK/T-cell lymphoma and analysis of serum inflammation and prognosis of patients

Purpose: To explore the efficacy of different regimens in nasal natural killer (NK)/T-cell lymphoma (NNKTL) and their effects on the serum inflammation and prognosis of patients. Methods: 146 NNKTL patients admitted to and treated in the Oncology Department of our hospital from January 2010 to December 2014 were randomly enrolled and divided into chemotherapy group (group A) and concurrent chemoradiotherapy group (group B). The expression levels of interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-a) before and after treatment were detected, the short-term efficacy was followed up and analyzed, and the correlation between the two was statistically analyzed. Results: In group A and group B, the total short-term effective rate was 71.87% and 84.97%, the 5-year overall survival (OS) rate was 39.9% and 66.2%, and the progression free survival (PFS) rate was 18.1% and 46.9%, respectively. Treatment regimens, clinical stage, the presence of B symptoms and lactate dehydrogenase (LDH) level were independent factors related to prognosis, and the remission rate after the first-course chemotherapy was an independent factor unrelated to prognosis. After treatment, there was no significant difference in the IL-2 level between the two groups of patients before and after treatment. The expression level of TNF-a after treatment was reduced compared with that before treatment, and the reduction was more obvious in group B. Conclusions: The short-term efficacy of concurrent chemoradiotherapy favors NNKTL, and the therapy can reduce the expression level of TNF-a.